NEWS HIGHLIGHTS
Published Studies Related to Paromomycin
Mirazid alone or combined with Paromomycin in treating cryptosporidiosis parvum in immunocompetent hospitalized patients. [2008.08]
Sixty cryptosporidiosis patients from Mansoura University Hospitals, 36 males and 24 females, with age from few months to ten years (mean age 6.1) were divided into three cross-matched groups of 20 patients each. All patients received the glutamine-based oral rehydration solution with 111 mmol/l glutamine, 20 mg zinc acetate once a day and vitamin A supplementation (200,000 IU) once a day for 2 weeks...
Injectable paromomycin for Visceral leishmaniasis in India. [2007.06.21]
BACKGROUND: Visceral leishmaniasis (kala-azar) affects large, rural, resource-poor populations in South Asia, Africa, and Brazil. Safe, effective, and affordable new therapies are needed. We conducted a randomized, controlled, phase 3 open-label study comparing paromomycin, an aminoglycoside, with amphotericin B, the present standard of care in Bihar, India... CONCLUSIONS: Paromomycin was shown to be noninferior to amphotericin B for the treatment of visceral leishmaniasis in India. (ClinicalTrials.gov number, NCT00216346.) Copyright 2007 Massachusetts Medical Society.
Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. [2006.09]
BACKGROUND: The optimal treatment for cutaneous leishmaniasis (CL) is not known. Topical paromomycin is one of the many drugs that have been suggested for the treatment of CL caused by Leishmania major. Recently, topical photodynamic therapy (PDT) has been reported to be effective in the treatment of CL. AIMS: To compare the parasitological and clinical efficacy of PDT vs. topical paromomycin in patients with Old World CL caused by L. major in Iran... CONCLUSION: Topical PDT can be used safely as a rapid and highly effective alternative treatment choice for Old World CL in selected patients.
Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. [2005.03]
This is an open study to compare the cure rate of cutaneous leishmaniasis caused by L. major and treated with either paromomycin sulfate or intralesional injection of meglumine antimoniate... The chi square test was used to compare the cure rate between the two groups and showed no significant difference (p = 0.85).
Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran. [2005.01]
Although pentavalent antimonials are often used in the first-line treatment of cutaneous leishmaniasis (CL), they have several adverse effects... Ointment containing 15% paromomycin therefore appears ineffective in the treatment of CL, at least when applied twice daily for 30 days to the lesions of cases from an endemic area of Isfahan, Iran.
Clinical Trials Related to Paromomycin
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis [Completed]
Symptomatic Visceral Leishmaniasis(VL)is fatal; Due to the increasing resistance to standard
therapy with antimonials, there is a need for new safe, efficacious, low-cost therapies for
the treatment of VL. Paromomycin is an off-patent aminoglycoside antibiotic with
anti-leishmaniasis activity. This study will test the safety and efficacy of paromomycin in
the treatment of patients with VL in India.
A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3 [Completed]
To determine the effectiveness of oral paromomycin sulfate for 21 days compared to placebo in
the treatment of cryptosporidiosis in patients with HIV infection. To evaluate the safety of
oral paromomycin at two different doses. To explore whether paromomycin administered over a
longer period provides additional benefit.
In previous studies, patients with cryptosporidiosis demonstrated dramatic improvement with
paromomycin therapy.
Treatment of Chronic Cryptosporidiosis in AIDS Patients [Terminated]
The purpose of this study is to see if it is safe and effective to add interleukin-12 (IL-12)
to the standard drug combination (paromomycin plus azithromycin) used to treat
cryptosporidiosis in AIDS patients. Doctors would like to find out if the combination of
IL-12, paromomycin, and azithromycin is more effective than paromomycin and azithromycin
alone.
Cryptosporidiosis is a type of opportunistic (AIDS-related) infection seen in HIV-positive
patients as their immune systems weaken. It is caused by a parasite that invades the
intestinal tract, and it can cause watery diarrhea, stomach cramps, an upset stomach, or a
fever. Antibiotics (paromomycin and azithromycin) are usually used to treat
cryptosporidiosis. In this study, doctors will look at the effectiveness of using IL-12.
IL-12 is a type of protein naturally produced by certain types of cells of the immune system
and is believed to be important for immune function. Doctors hope that IL-12 can help boost
the immune system in fighting cryptosporidiosis.
An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis [Recruiting]
It is a randomized, double-blind, multi-center, two-arm study intended to assess the safety
and efficacy of three different doses/dose regimens of paromomycin administered
intramuscularly as follows: 11 mg/kg/day for 14 days and 11 mg/kg/day for 21 days for the
treatment of visceral leishmaniasis (VL) in India.
Pilot Randomized Study of Paromomycin (Aminosidine) Vs Streptomycin for Uncomplicated Pulmonary Tuberculosis [Completed]
OBJECTIVES: I. Compare the pharmacokinetics and early bactericidal activity of paromomycin
(aminosidine) vs streptomycin for the treatment of uncomplicated pulmonary tuberculosis.
II. Compare the tolerability of these two drugs in these patients. III. Establish the
relationships between achieved serum concentration, minimal inhibitory concentration, and
early bactericidal activity of paromomycin and streptomycin.
|
